A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer

Trial Profile

A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Duligotuzumab (Primary) ; Cetuximab; Fluorouracil; Folic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 05 Mar 2018 Results (Data cut off 26 November 2014) assessing safety and efficacy published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 17 Feb 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 23 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top